Dalfampridine (4-aminopyridine)
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317577

CAS#: 504-24-5

Description: Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. It has been approved by the FDA for use as a treatment for multiple sclerosis.


Price and Availability

Size
Price

1g
USD 150
Size
Price

2g
USD 250
Size
Price

5g
USD 350

Dalfampridine (4-aminopyridine), purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 317577
Name: Dalfampridine (4-aminopyridine)
CAS#: 504-24-5
Chemical Formula: C5H6N2
Exact Mass: 94.0531
Molecular Weight: 94.11
Elemental Analysis: C, 63.81; H, 6.43; N, 29.77


Synonym: 4-aminopyridine; Pyridin-4-amine; Fampridine; 4-Pyridinamine; 504-24-5; 4-Pyridylamine

IUPAC/Chemical Name: pyridin-4-amine

InChi Key: NUKYPUAOHBNCPY-UHFFFAOYSA-N

InChi Code: InChI=1S/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7)

SMILES Code: C1=CN=CC=C1N


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Li G, Liu ZL, Zhang WN, Yang K. Blockade of presynaptic 4-aminopyridine-sensitive potassium channels increases initial neurotransmitter release probability, reinstates synaptic transmission altered by GABAB receptor activation in rat midbrain periaqueductal gray. Neuroreport. 2016 Jan 6;27(1):50-5. doi: 10.1097/WNR.0000000000000499. PubMed PMID: 26575285.

2: Keune PM, Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U, Oschmann P, Muenssinger J. Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine). BMC Neurol. 2015 Sep 24;15:171. doi: 10.1186/s12883-015-0431-0. PubMed PMID: 26400041; PubMed Central PMCID: PMC4581460.

3: Laura MC, Xóchitl FP, Anne S, Alberto MV. Analysis of connexin expression during seizures induced by 4-aminopyridine in the rat hippocampus. J Biomed Sci. 2015 Aug 14;22:69. doi: 10.1186/s12929-015-0176-5. PubMed PMID: 26268619; PubMed Central PMCID: PMC4535691.

4: Golovko V, Gonotkov M, Lebedeva E. Effects of 4-aminopyridine on action potentials generation in mouse sinoauricular node strips. Physiol Rep. 2015 Jul;3(7). pii: e12447. doi: 10.14814/phy2.12447. PubMed PMID: 26156968; PubMed Central PMCID: PMC4552527.

5: Dojer B, Pevec A, Belaj F, Kristl M. Two new zinc(II) acetates with 3- and 4-aminopyridine: syntheses and structural properties. Acta Chim Slov. 2015;62(2):312-8. PubMed PMID: 26085412.

6: Del Pino J, Frejo MT, Baselga MJ, Capo MA, Moyano P, García JM, Díaz MJ. Neuroprotective or neurotoxic effects of 4-aminopyridine mediated by KChIP1 regulation through adjustment of Kv 4.3 potassium channels expression and GABA-mediated transmission in primary hippocampal cells. Toxicology. 2015 Jul 3;333:107-17. doi: 10.1016/j.tox.2015.04.013. Epub 2015 Apr 24. PubMed PMID: 25917026.

7: Zhao M, McGarry LM, Ma H, Harris S, Berwick J, Yuste R, Schwartz TH. Optical triggered seizures using a caged 4-Aminopyridine. Front Neurosci. 2015 Feb 4;9:25. doi: 10.3389/fnins.2015.00025. eCollection 2015. PubMed PMID: 25698919; PubMed Central PMCID: PMC4316705.

8: Chang WP, Lu HC, Shyu BC. Treatment with direct-current stimulation against cingulate seizure-like activity induced by 4-aminopyridine and bicuculline in an in vitro mouse model. Exp Neurol. 2015 Mar;265:180-92. doi: 10.1016/j.expneurol.2015.02.002. Epub 2015 Feb 12. PubMed PMID: 25682917.

9: Braga Ade F, Carvalho VH, Braga FS, Potério GM, Santos FN. [Effect of ropivacaine combined with pancuronium on neuromuscular transmission and effectiveness of neostigmine and 4-aminopyridine for blockade reversal: experimental study]. Rev Bras Anestesiol. 2015 Mar-Apr;65(2):136-40. doi: 10.1016/j.bjan.2013.10.020. Epub 2014 Nov 8. Portuguese. PubMed PMID: 25666937.

10: Borbély S, Czégé D, Molnár E, Dobó E, Mihály A, Világi I. Repeated application of 4-aminopyridine provoke an increase in entorhinal cortex excitability and rearrange AMPA and kainate receptors. Neurotox Res. 2015 May;27(4):441-52. doi: 10.1007/s12640-014-9515-7. Epub 2015 Jan 10. PubMed PMID: 25576253.